News brief­ing: Bio­gen gets a quick date with an FDA pan­el for con­tro­ver­sial ad­u­canum­ab; Abeona CEO, board mem­bers ex­it — shares im­plode

Mark your cal­en­dars for No­vem­ber 6, which looms as the next ma­jor test for Bio­gen’s ad­u­canum­ab. That’s the day the FDA has set aside for a pan­el re­view of the drug, which will be pre­ced­ed by an in-house re­port on the pros and cons of the con­tro­ver­sial drug.

The big biotech $BI­IB gained steam on the news that the FDA had of­fered a pri­or­i­ty re­view for the Alzheimer’s drug, which suc­ceed­ed in one late-stage study and failed in an­oth­er, on­ly to be res­ur­rect­ed on the ba­sis of some deep dives in­to sub­group da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA